Year: 2025

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Partners Value Split Corp. (the “Company”) announced today that it has entered into an agreement to sell 4,000,000 Class AA Preferred Shares, Series 17 (the “Series 17 Preferred Shares”) to a syndicate of underwriters led by Scotiabank, BMO Capital Markets, CIBC Capital Markets, RBC Capital Markets and TD Securities Inc. on a bought deal basis. The Series 17 Preferred Shares will be issued at a price of US$25.00 per share, for gross proceeds of US$100,000,000. The Series 17 Preferred Shares will carry a fixed coupon of 5.25% and will have a final maturity of January 31, 2033. The Series 17 Preferred Shares have a provisional rating of Pfd-2 from DBRS Limited. The net proceeds of the offering will be used...

UTime LimitedUTime Limited Actively Expands Global Smart Wearable Device MarketUTime LimitedSmart Wearable DevicesSHENZHEN, China, Nov. 05, 2025 (GLOBE NEWSWIRE) — UTime Limited (Nasdaq: WTO) today announced that it is actively promoting its smart wearable devices to more international markets through its existing global distribution channels and partner network.Leveraging its experience in supply chain management and product development accumulated in the mobile device sector, the company is committed to introducing its newly launched health-focused smart wearable products, including smartwatches and smart rings, to multiple overseas markets where it has established business connections. The company believes that its products’ balance of functional design and cost-effectiveness will help them gain competitiveness...

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9, 2025, in Houston, Texas. The poster will be presented as part of the session “Glomerular Clinical Trials: From Data to Impact” on Friday, November 7, 2025, from 10:00 a.m. to 12:00 p.m. Central Time. The poster board number is FR-PO0829. PCS499 is an analog of a metabolite of pentoxifylline (PTX). PTX has been shown to decrease proteinuria...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company’s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data,...

New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “HiFi sequencing accurately identifies clinically relevant variants in paralogous genes.” The study shows that PacBio HiFi sequencing combined with Paraphase, a dedicated haplotype-based variant caller, uncovered all known clinically relevant variants present in the study population – even in the hardest-to-sequence regions of the genome – demonstrating its readiness...

Oslo, 5 November 2025: Scatec ASA (“Scatec”) has successfully issued a NOK 1,000 million 4.25-year senior unsecured green bond issue with a coupon of 3 months NIBOR + 2.85% p.a. The net proceeds of the green bond issue shall be applied towards repayment of outstanding corporate interest-bearing debt and general corporate purposes as set out in the Green Financing Framework. The bond will extend Scatec’s corporate maturity profile and enhance its financial flexibility. Scatec remains committed to continue deleveraging on corporate level, targeting NOK 4 billion in gross corporate interest-bearing debt by 2030. Arctic Securities, DNB Carnegie, Nordea and SB1 Markets acted as Joint Lead Managers in connection with the placement of the new bond issue. An application will be made for the bonds to be listed on Oslo Børs. For further...

Supports Rapidly Growing GaN Device Market Driven by Demand for Power Efficiency for Data Center, Industrial, and Automotive Applications PLAINVIEW, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (NASDAQ: VECO) announced today receipt of an order for a Propel®300 system from a major power semiconductor integrated device manufacturer (IDM) for gallium nitride (GaN) epitaxy on 300mm silicon (Si) wafers. This order cements Veeco’s position as a leader in 300mm MOCVD technology, building on years of experience including previous shipments of the Propel®300 platform for various applications across the compound semiconductor industry. “Qualifying Propel®300 for 300mm GaN-on-Si epitaxy for power devices is a significant achievement in the path to widespread adoption of GaN technology,” commented Anil Vijayendran, Vice President,...